China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Want to cut your energy bills? Here’s how five experts are doing it 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
PHILADELPHIA and OXFORD, United Kingdom, March 02, 2017 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday March 7, 2017 at 10:40-11:10 AM EST (3:40-4:10 PM GMT). The conference is being held at the Boston Marriott Copley Plaza. Adaptimmune’s presentation will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 30 days following the conference.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR® (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com
Adaptimmune Contacts Investor Relations Will Roberts T: (215) 825-9306 E: [email protected] Juli P. Miller, Ph.D. T: (215) 825-9310 E: [email protected] Media Relations Margaret Henry T: +44 (0)1235 430036 Mobile: +44 (0)7710 304249 E: [email protected]
